Hydroxyurea can eliminate transfusion requirements in children with severe β-thalassemia-Reference-Cited by-同舟云学术

Hydroxyurea can eliminate transfusion requirements in children with severe β-thalassemia

Published:2003-08-15 Issue:4 Volume:102 Page:1529-1530
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Bradai Mohamed¹,Abad Mohand Tayeb¹,Pissard Serge¹,Lamraoui Fatima¹,Skopinski Laurent¹,de Montalembert Mariane¹

Affiliation:

1. From the Service d'Hématologie, Hôpital Franz Fanon, Blida, Algeria; Laboratoire de Génétique Moléculaire and Institut National de la Santé etdela Recherche Médicale (INSERM) U 468, Hôpital Henri Mondor, Créteil, France; and Service de Pédiatrie Générale, Hôpital Necker-Enfants Malades, Paris, France.

Abstract

Abstract Hydroxyurea (HU) enhances fetal hemoglobin (Hb) production. An increase in total Hb level has been repeatedly reported during HU treatment in patients with sickle cell disease and in several patients with β-thalassemia intermedia. Effects in patients with β-thalassemia major are controversial. We now report a marked elevation of total Hb levels with HU that permitted regular transfusions to be stopped in 7 children with transfusion-dependent β-thalassemia. The median follow-up was 19 ± 3 months (range, 13-21 months). We conclude that HU can eliminate transfusional needs in children with β-thalassemia major, which could be particularly useful in countries such as Algeria, where supplies of blood or chelating agents are limited.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/102/4/1529/1689514/h81603001529.pdf

Reference11 articles.

1. Charache S, Terrin ML, Moore RD, et al. Effects of hydroxyurea on the frequency of painful crises in sickle cell anemia. N Engl J Med.1995;332: 1317-1322.

2. De Montalembert M, Bégué P, Bernaudin F, Thuret I, Bachir D, Micheau M. Preliminary report of a toxicity study of hydroxyurea in sickle cell disease. Arch Dis Child. 1999;81: 437-439.

3. Zeng YT, Huang SZ, Ren ZR, et al. Hydroxyurea therapy in β-thalassaemia intermedia: improvement in haematological parameters due to enhanced β-globin synthesis. Br J Haematol.1995; 90: 557-563.

4. Rigano P, Manfre L, La Galla R, et al. Clinical and hematological responses to hydroxyurea in a patient with Hb Lepore/beta-thalassemia. Hemoglobin. 1997;21: 219-226.

5. Olivieri NF. Reactivation of fetal hemoglobin in patients with β-thalassemia. Semin Hematol.1996;33: 24-42.

Cited by 101 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Adverse effects of hydroxyurea used for the treatment of myeloproliferative neoplasms;Journal of the Korean Medical Association;2023-04-10

2. Gene Therapy for β-Hemoglobinopathies: From Discovery to Clinical Trials;Viruses;2023-03-09

3. Foetal haemoglobin inducers for reducing blood transfusion in non-transfusion-dependent beta-thalassaemias;Cochrane Database of Systematic Reviews;2023-01-13

4. A randomised double-blind placebo-controlled clinical trial of oral hydroxyurea for transfusion-dependent β-thalassaemia;Scientific Reports;2022-02-17

5. IVS I-5 (G > C) is associated with changes to the RBC membrane lipidome in response to hydroxyurea treatment in β-thalassemia patients;Molecular Omics;2022